ФУНДАМЕНТАЛЬНЫЕ ОСНОВЫ ПОИСКА ЛЕКАРСТВЕННЫХ СРЕДСТВ ДЛЯ ТЕРАПИИ САХАРНОГО ДИАБЕТА 2-ГО ТИПА
- Авторы: Спасов А.А.1, Петров В.И.1, Чепляева Н.И.1, Ленская К.В.1
-
Учреждения:
- Волгоградский государственный медицинский университет, Российская Федерация
- Выпуск: Том 68, № 2 (2013)
- Страницы: 43-49
- Раздел: АКТУАЛЬНЫЕ ВОПРОСЫ ЭНДОКРИНОЛОГИИ
- Дата публикации:
- URL: https://vestnikramn.spr-journal.ru/jour/article/view/214
- DOI: https://doi.org/10.15690/vramn.v68i2.548
- ID: 214
Цитировать
Полный текст
Аннотация
В обзоре проанализированы литературные данные о поиске новых препаратов для лечения сахарного диабета, направленных на коррекцию трех основных метаболических нарушений, приводящих к гипергликемии: дисфункции β-клеток, периферической инсулинорезистентности, избыточной продукции глюкозы печенью.
Ключевые слова
Об авторах
А. А. Спасов
Волгоградский государственный медицинский университет, Российская Федерация
Автор, ответственный за переписку.
Email: aspasov@mail.ru
PhD, Professor, RAMS academician, Honored Worker of Science of Russian Federationa, Head of Department for Pharmacology, Volgograd State Medical University. Address: 400131, Volgograd, Pavshikh Bortsov Sq., 1; tel.: (8442) 94-24-23 Россия
В. И. Петров
Волгоградский государственный медицинский университет, Российская Федерация
Email: post@volgmed.ru
PhD, Professor, RAMS academician, Honored Worker of Science of Russian Federation, Honored Doctor of Russian Federation, Chancellor of Volgograd State Medical University Address: 400131, Volgograd, Pavshikh Bortsov Sq., 1; tel.: (8442) 55-17-70 Россия
Н. И. Чепляева
Волгоградский государственный медицинский университет, Российская Федерация
Email: natalja-chepljaeva@rambler.ru
Junior Research Worker, Laboratory of Antioxidants Pharmacology, Research Institute of Pharmacology, Volgograd State Medical University Address: 400131, Volgograd, Pavshikh Bortsov Sq., 1; tel.: (8442) 97-15-34 Россия
К. В. Ленская
Волгоградский государственный медицинский университет, Российская Федерация
Email: kina81@mail.ru
PhD, Doctoral Student of Pharmacology Department, Volgograd State Medical University Address: 400131, Volgograd, Pavshikh Bortsov Sq., 1; tel.: (8442) 97-15-34
РоссияСписок литературы
- Dedov I.I., Shestakova M.V., Suncov Ju.I. et al. Pharmacoeconomic modeling of long-term results of treatment of type 2 diabetes in patients treated with modern analogues of insulin therapy compared with oral antidiabetes drugs. Saharnyi diabet = Diabetes. 2010; 46 (1): 102–112.
- Balabolkin M.I., Klebanova E.M., Kreminskaya V.M. Treatment of diabetes and its complications. Moscow, 2005.
- Ametov A.S. The role of β-cells in the regulation of glucose homeostasis in normal and type 2 diabetes. Saharnyi diabet = Diabetes. 2008; 41 (4): 6–12.
- Stolar M.W., Hoogwerf B.J., Gorshow S.M. et al. Managing Type 2 Diabetes: Going Beyond Glycemic Control. J. Manag. Care Pharm. 2008; 14 (5): 2–19.
- Lerario A.C., Chacra A.R., Pimazoni-Netto A. et al. Algorithm for the treatment of type 2 diabetes: a position statement of Brazilian Diabetes Society. Diabetology& Metabolic Syndrome. 2010; 35 (2).
- Dedov I.I., Shestakova M.V. Algorithms for specialized medical care to patients with diabetes mellitus. Moscow, 2007.
- Spasov A.A., Chepurnova M.V. Scientific approaches to the combined treatment of diabetes type 2. Vestnik VolgGMU = Bulletin of Volgograd State Medical University. 2011; 1: 8–12.
- Saharnyi diabet: diagnostika, lechenie, profilaktika. Pod red. I.I. Dedova, M.V. Shestakovoi [Diabetis: Diagnosis. Treatment, Prophylaxis. Edited by I.I. Dedov, M.V. Shestakova]. Moscow, MIA, 2011. 808 p.
- O’Moore-Sullivan T.M., Prins J.B. Thiazolidinediones and type 2 diabetes: new drugs for an old disease. MJA. 2002; 116: 381–386.
- Graham D.J., Ouellet-Hellstrom R., MaCurdy T.E. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010; 304 (4): 411–418.
- Levien, T.L., Baker DE. New drugs in development for the treatment of diabetes. Diabetes Spectrum. 2009; 22: 92–106.
- Sharma R. Novel dual-acting peroxisome proliferator-activated receptor alpha and gamma agonists. J. Clin. Diagn. Res. 2008; 2: 659–667.
- Johnson T.O., Ermolieff J., Jirousek M.R. Protein tyrosine phosphatase 1b inhibitors for diabetes. Drug discovery. 2002; 1: 696–709.
- Ukkola O., Santaniemi M. Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities. J. Intern. Med. 2002; 251: 467–475.
- Kumar Vats R., Kumar V., Kothari A. et al. Emerging targets for diabetes. Curr. sci. 2005; 88 (2): 241–249.
- Black E., Breed J., Breeze A. L. et al. Structure-based design of protein tyrosine phosphatase-1B inhibitors. Bioorg. & Medicinal Chem. 2005; 15: 2503–2507.
- Wilson D.P., Wan Z.K., Xu W.X. et al. Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site. J. Med. Chem. 2007; 50: 4681–4698.
- Coman O.A., Paunescu H., Ghita I. et al. Beta 3 adrenergic receptors: molecular, histological, functional and pharmacological approaches. Romanian J. Morphol. Embryol. 2009; 50 (2): 169–179.
- Schaeffer P., Bernat A., Arnone M. et al. Effect of SR58611A, a potent beta-3 adrenoceptor agonist, on cutaneous wound healing in diabetic and obese mice. Eur. J. Pharmacol. 2006; 529 (1–3): 172–178.
- Francke S. TAK-677 (Dainippon/Takeda). Curr. Opin. Investig. Drug. 2002; 11 (3): 1624–1628.
- Sakurai H.A New concept: the use of vanadium complexes in the treatment of diabetes mellitus. Chem. Rec. 2002; 2: 237–248.
- Thompson K.H., Lichter J., Le Be C. Vanadium treatment of type 2 diabetes: A view to the future. J. Inorganic Biochem. 2009; 103: 554–558.
- Gallwitz B. The evolving place of incretin-based therapies in type 2 diabetes. Pediatr. Nephrol. 2010; 25: 1207–1217.
- Ranganath L.R. The entero-insular axis: implications for human metabolism. Clin. Chem. Lab. Med. 2008; 46 (1): 43–56.
- Ross A.S. Incretin agents in type 2 diabetes. Can. Fam. Physician. 2010; 56: 639–648.
- Dharmalingam M., Sriram U., Baruah M.P. Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus. Indian J. Endocrinol. Metab. 2011; 15 (1): 9–17.
- Chena D., Liaoa J., Lia N. et al. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/ db mice. PNAS. 2007; 104 (3): 943–948.
- Gorrell M.D. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin. Sci. 2005; 108: 277–292.
- Gupta R, Walunj S.S., Tokala R.K. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of type 2 diabetes. Curr. Drug Targets. 2009; 10: 71–87.
- Green B.D., Flatt P.R. Incretin hormone mimetics and analogues in diabetes therapeutics. Best Pract. Res. Clin. Endocrinol. Metab. 2007; 4 (21): 497–516.
- Overton H.A., Fyfe M.C.T., Reynet C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Brit. J. Pharmacol. 2008; 153: 76–81.
- Spasov A.A., Bulanov A.E., Samohina M.P. Antidiabetic properties of Gymnema sylvestre (review). Himiko-farmacevticheskij zhurnal = Chemistry and pharmaceutical journal. 2008; 42 (11): 10–14.
- Fushiki T., Kojima A., Imoto T. An extract of Gymnema sylvestre leaves and purified gymnemic acid inhibits glucose-stimulated gastric inhibitory peptide secretion in rats. J. Nutr. 1992; 122: 2367–2373.
- Matschinsky F.M. Assessing the potential of glucokinase activators in diabetes therapy. Nat. Rev. Drug Disc. 2009; 8: 399–416.
- Matschinsky F.M., Porte D. Glucokinase activators (GKAs) promise a new pharmacotherapy for diabetics. F1000. Med. Reports. 2010; 43 (2): 1776–1783.
- Spasov A.A., Petrov V.I., Anisimova V.A. et al. Materialy IV Vserossiiskogo diabetologicheskogo kongressa [Proceedings of 4th Russian National Diabetic Congress]. Moscow, 2008. 336 p.
- Fujimoto K., Polonsky K. S. Pdx1 and other factors that regulate pancreatic в-cell survival. Diabetes Obes. Metab. 2009; 11 (Suppl. 4.): 30–37.
- Robertson R.P., Harmon J.S. Pancreatic islet β-cell and oxidative stress: the importance of glutathione peroxidase. FEBS Lett. 2007; 581 (19): 3743–3748.
- Poltorak V.V., Gorbenko N.I., Sakalo E.A. Prevention of type 1 diabetes mellitus: pathophysiological rationale,
- strategy and clinical implementation. Ukrainskii medicinskiij chasopis = Ukranian medical bulletin. 2001; 22 (2): 83–91.
- Yonemura, Y., Takashima T., Miwa K. et al. Amelioration of diabetes mellitus in partially depancreatized rats by poly(ADP-ribose) synthetase inhibitors: evidence of islet B-cell regeneration. Diabetes. 1984; 33: 401–404.
- Sandler S., Andersson A. Stimulation of cell replication in transplanted pancreatic islets by nicotinamide treatment. Transplantation. 1988; 46: 30–31.
- Manna R., Migliore A., Martin L.S. et al. Nicotinamide treatment in subjects at high risk of developing IDDM improves insulin secretion. Brit. J. Clin. Pract. 1992; 46: 177–179.
- Hu Y., Wang Y., Wang L. et al. Effects of nicotinamide on prevention and treatment of streptozotocin-induced diabetes mellitus in rats. Chin. Med. J. (Engl.). 1996; 109 (11): 819–822.
- Pozzilli P., Visalli N., Cavallo M.G. Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study). Eur. J. Endocrinol. 1997; 137: 234–239.
- Crino A., Schiaffini R., Manfrini S. A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX). Eur. J. Endocrinol. 2004; 150: 719–724.
- Zhou S.-S., Li D., Sun W.-P. Nicotinamide overload may play a role in the development of type 2 diabetes. World J. Gastroenterol. 2009; 43 (15): 5674–5684.
- Jagtap P. G., Baloglu E., Southan G. J. et al. Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J. Med. Chem. 2005; 48: 5100–5103.
- Szabo C., Biser A., Benko R. et al. Poly(ADP-Ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice. Diabetes. 2006; 55 (11): 3004–3012.
- Pittenger G.L., Taylor-Fishwick D., Vinik A.I. The role of islet neogeneis-associated protein (INGAP) in pancreatic islet neogenesis. Curr. Protein Pept Sci. 2009; 10 (1): 37–45.
- Dungan K.M., Buse J.B., Ratner R.E. Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). Diabetes Metab. Res. Rev. 2009; 25 (6): 558–565.
- Bottino R., Balamurugan A.N., Tse H. Response of human islets to isolation stress and the effect of antioxidant treatment. Diabetes. 2004; 53: 2559–2568.
- Felig P., Wahren J. Influence of endogenous insulin secretion on splanchnic glucose and amino acid metabolism in man. J. Clin. Invest. 1971; 50 (8): 1702–1711.
- Wu C., Okar D. A., Kang J. et al. Reduction of hepatic glucose production as a therapeutic target in the treatment of diabetes. Curr. Drug Targets Immune, Endocrine & Metab. Dis. 2005; 5: 51–59.
- Alice Y.Y., Cheng I., Fantus G. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ. 2005; 172 (2): 213–226.
- Long Y.C., Zierath J.R. AMP-activated protein kinase signaling in metabolic regulation. J. Clin. Invest. 2006; 116: 1776–1783.
- Meijer L., Flajolet M., Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends in Pharmacol. Sci. 2004; 25 (9): 471–480.
- Woodgett J.R. Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders. Curr. Drug Targets Immune, Endocrine & Metab. Dis. 2003; 3: 275–284.
- Bergans N., Stalmans W., Goldmann S. et al. Molecular mode of inhibition of glycogenolysis in rat liver by the dihydropyridine derivative, BAY R3401: inhibition and inactivation of glycogen phosphorylase by an activated metabolite. Diabetes. 2000; 49(9): 1419–1426.
- Martin W.H., Hoover D.J., Armento S.J. et al. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. PNAS. 1998; 95 (4): 1776–1781.
- Herling A.W., Burger H.-J., Schwab D. Pharmacodynamic profile of a novel inhibitor of the hepatic glucose-6-phosphatase system. Am. J. Physiol. 1998; 274: 1087–1093.
- Gallagher M.P., Goland R.S., Greenbaum C.J. Making progress: preserving beta cells in type 1 diabetes. Ann. N.-Y. Acad. Sci. 2011; 1243: 119–134.
- Bhaskar V., Goldfine I.D., Bedinger D.H. et al. A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control. Diabetes. 2012; 61 (5): 1263–1271.
- Petrov V.I., Rogova N.V., Ryazanova A.Ju. et al. Ultra-low doses of antibodies to the C-terminal fragment of β-subunit of the insulin receptor - a new class of antidiabetic agents. Byulleten' VNC RAMN = Bulletin of RAMS Volgograd RI. 2009; 3: 19–22.
- Gu W., Yan H., Winters K. A. et al. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible β-cell hyperplasia and hyperglucagonemia. J. Pharmacol. Exp. Therapeutics. 2009; 331 (3): 871–881.
- Jabbour S.A. The importance of reducing hyperglycemia while preserving insulin secretion — the rationale for sodium-coupled glucose co-transporter 2 inhibition in diabete. US Endocrinol. 2009; 5: 75–78.
- Norton L., De Fronzo R.A., Abdul-Ghani M.A. Sodium-glucose co-transporter 2 inhibition — a novel strategy for glucose control in type 2 diabetes. US Endocrinol. 2010; 6: 42–47.
- Chao E.C., Henry R.R. SGLT2 inhibition — a novel strategy for diabetes treatment. Nat. Rev. Drug Discov. 2010; 9 (7): 551–559.